aTyr Pharma, Inc. (LIFE) Receives $4.81 Consensus Target Price from Brokerages

aTyr Pharma, Inc. (NASDAQ:LIFE) has earned a consensus recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $4.81.

A number of brokerages have commented on LIFE. Zacks Investment Research cut shares of aTyr Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. ValuEngine cut shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st.

Shares of aTyr Pharma (NASDAQ LIFE) traded down $0.05 during mid-day trading on Wednesday, reaching $3.90. 62,842 shares of the company’s stock were exchanged, compared to its average volume of 32,839. aTyr Pharma has a twelve month low of $2.30 and a twelve month high of $6.50. The stock has a market capitalization of $117.54, a PE ratio of -1.92 and a beta of 3.83. The company has a current ratio of 9.49, a quick ratio of 9.49 and a debt-to-equity ratio of 0.17.

aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.07. sell-side analysts predict that aTyr Pharma will post -1.93 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. Artal Group S.A. purchased a new stake in shares of aTyr Pharma in the third quarter worth $1,263,000. Victory Capital Management Inc. purchased a new stake in shares of aTyr Pharma in the third quarter worth $455,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of aTyr Pharma by 44.1% in the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 25,676 shares in the last quarter. 58.28% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.themarketsdaily.com/2018/01/14/atyr-pharma-inc-life-receives-4-81-consensus-target-price-from-brokerages.html.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply